> top > docs > PubMed:19176376 > annotations

PubMed:19176376 JSONTXT

Annnotations TAB JSON ListView MergeView

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-119 Sentence denotes A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.
TextSentencer_T2 120-184 Sentence denotes The tumor antigen NY-ESO-1 is a promising cancer vaccine target.
TextSentencer_T3 185-341 Sentence denotes We describe here a novel HLA-B7-restricted NY-ESO-1 epitope, encompassing amino acids 60-72 (APRGPHGGAASGL), which is naturally presented by melanoma cells.
TextSentencer_T4 342-426 Sentence denotes The tumor epitope bound to HLA-B7 by bulging outward from the peptide-binding cleft.
TextSentencer_T5 427-648 Sentence denotes This bulged epitope was not an impediment to T-cell recognition, however, because four of six HLA-B7(+) melanoma patients vaccinated with NY-ESO-1 ISCOMATRIX vaccine generated a potent T-cell response to this determinant.
TextSentencer_T6 649-872 Sentence denotes Moreover, the response to this epitope was immunodominant in three of these patients and, unlike the T-cell responses to bulged HLA class I viral epitopes, the responding T cells possessed a remarkably broad TCR repertoire.
TextSentencer_T7 873-1162 Sentence denotes Interestingly, HLA-B7(+) melanoma patients who did not receive the NY-ESO-1 ISCOMATRIX vaccine rarely generated a spontaneous T-cell response to this cryptic epitope, suggesting a lack of priming of such T cells in the natural anti-NY-ESO-1 response, which may be corrected by vaccination.
TextSentencer_T8 1163-1289 Sentence denotes Together, our results reveal several surprising aspects of antitumor immunity and have implications for cancer vaccine design.
T1 0-119 Sentence denotes A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.
T2 120-184 Sentence denotes The tumor antigen NY-ESO-1 is a promising cancer vaccine target.
T3 185-341 Sentence denotes We describe here a novel HLA-B7-restricted NY-ESO-1 epitope, encompassing amino acids 60-72 (APRGPHGGAASGL), which is naturally presented by melanoma cells.
T4 342-426 Sentence denotes The tumor epitope bound to HLA-B7 by bulging outward from the peptide-binding cleft.
T5 427-648 Sentence denotes This bulged epitope was not an impediment to T-cell recognition, however, because four of six HLA-B7(+) melanoma patients vaccinated with NY-ESO-1 ISCOMATRIX vaccine generated a potent T-cell response to this determinant.
T6 649-872 Sentence denotes Moreover, the response to this epitope was immunodominant in three of these patients and, unlike the T-cell responses to bulged HLA class I viral epitopes, the responding T cells possessed a remarkably broad TCR repertoire.
T7 873-1162 Sentence denotes Interestingly, HLA-B7(+) melanoma patients who did not receive the NY-ESO-1 ISCOMATRIX vaccine rarely generated a spontaneous T-cell response to this cryptic epitope, suggesting a lack of priming of such T cells in the natural anti-NY-ESO-1 response, which may be corrected by vaccination.
T8 1163-1289 Sentence denotes Together, our results reveal several surprising aspects of antitumor immunity and have implications for cancer vaccine design.

DisGeNET

Id Subject Object Predicate Lexical cue
T0 65-78 gene:404663 denotes tumor antigen
T1 97-103 disease:C0006826 denotes cancer
T2 65-78 gene:404663 denotes tumor antigen
T3 97-103 disease:C1306459 denotes cancer
T4 138-146 gene:1485 denotes NY-ESO-1
T5 162-168 disease:C1306459 denotes cancer
T6 138-146 gene:1485 denotes NY-ESO-1
T7 162-168 disease:C0006826 denotes cancer
T8 138-146 gene:246100 denotes NY-ESO-1
T9 162-168 disease:C0006826 denotes cancer
T10 124-137 gene:404663 denotes tumor antigen
T11 162-168 disease:C1306459 denotes cancer
T12 124-137 gene:404663 denotes tumor antigen
T13 162-168 disease:C0006826 denotes cancer
T14 138-146 gene:246100 denotes NY-ESO-1
T15 162-168 disease:C1306459 denotes cancer
T16 228-236 gene:1485 denotes NY-ESO-1
T17 326-334 disease:C0025202 denotes melanoma
T18 228-236 gene:246100 denotes NY-ESO-1
T19 326-334 disease:C0025202 denotes melanoma
R1 T0 T1 associated_with tumor antigen,cancer
R2 T2 T3 associated_with tumor antigen,cancer
R3 T4 T5 associated_with NY-ESO-1,cancer
R4 T6 T7 associated_with NY-ESO-1,cancer
R5 T8 T9 associated_with NY-ESO-1,cancer
R6 T10 T11 associated_with tumor antigen,cancer
R7 T12 T13 associated_with tumor antigen,cancer
R8 T14 T15 associated_with NY-ESO-1,cancer
R9 T16 T17 associated_with NY-ESO-1,melanoma
R10 T18 T19 associated_with NY-ESO-1,melanoma

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
19176376-2#43#51#gene1485 228-236 gene1485 denotes NY-ESO-1
19176376-2#43#51#gene246100 228-236 gene246100 denotes NY-ESO-1
19176376-2#141#149#diseaseC0025202 326-334 diseaseC0025202 denotes melanoma
43#51#gene1485141#149#diseaseC0025202 19176376-2#43#51#gene1485 19176376-2#141#149#diseaseC0025202 associated_with NY-ESO-1,melanoma
43#51#gene246100141#149#diseaseC0025202 19176376-2#43#51#gene246100 19176376-2#141#149#diseaseC0025202 associated_with NY-ESO-1,melanoma

DisGeNet-2017-sample

Id Subject Object Predicate Lexical cue
T2863 228-236 gene:1485 denotes NY-ESO-1
T2864 326-334 disease:C0025202 denotes melanoma
R1 T2863 T2864 associated_with NY-ESO-1,melanoma
R2 T2863 T2864 associated_with NY-ESO-1,melanoma

UBERON-AE

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 432-438 http://purl.obolibrary.org/obo/UBERON_0018306 denotes bulged
PD-UBERON-AE-B_T2 770-776 http://purl.obolibrary.org/obo/UBERON_0018306 denotes bulged

performance-test

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 379-386 http://purl.obolibrary.org/obo/UBERON_0018306 denotes bulging
PD-UBERON-AE-B_T2 432-438 http://purl.obolibrary.org/obo/UBERON_0018306 denotes bulged
PD-UBERON-AE-B_T3 770-776 http://purl.obolibrary.org/obo/UBERON_0018306 denotes bulged